Clive Brook

Synexus Clinical Research Ltd. offers clinical trials and biological research services. It offers clinical trial management, project management, medical imaging and medical procedures. The company was founded in 1998 and is headquartered in Lancashire, the United Kingdom.

Gentronix Ltd. provides services and solutions to help organizations optimize the development of drugs and other chemicals. It provides contract services for genotoxicity using a patented human cell GADD45a reporter GreenScreen HC and BlueScreen HC assays and related assays including Micronucleus and Ames MPF. The company was founded by Richard Maurice Walmsley in July 1999 and is headquartered in Macclesfield, the United Kingdom.

Reaxa Ltd. manufactures and distributes products and technologies for the chemical industry. Its products include EnCat, QuadraPure, QuadraSil and LaPCat. The company was founded by Steven V. Ley, Ian R. Baxendale and Peter Jackson in 2004 and is headquartered in Manchester, the United Kingdom.

Capital for Enterprise Fund Managers Ltd is a private equity firm founded in 2008. The firm is headquartered in the UK.

Unibio International Plc is a leading British sustainable protein company that specializes in producing single-cell protein for animal feed. The company is based in London, UK, and David Henstrom has been the CEO since 2021. The company has won several awards for its environmentally friendly practices, including the "Kalundborg Business Council's Green Environment and Climate Award." Unibio has participated in various exhibitions and conferences worldwide, including the "Forum for Innovations in Agriculture" in 2018 and the "Deutsche Messe Hannover" in 2018.

Future Meds Ltd. is a fast-growing independent research site network that supports pharmaceutical companies, sponsors, and CROs in finding effective treatments and medications for patients. The private company is based in Bromborough, UK, and has subsidiaries in Germany and the United Kingdom. The British company's dedicated research site teams aim to accelerate study timelines, streamline processes, lower costs, and improve data quality to help patients access new treatments faster. Future Meds is a network of modern dedicated research sites that conduct clinical trials using innovative technologies to make them available to as many patients as possible. The company was founded in 2020, and Radoslaw Janiak has been the CEO since 2019.